# Bioventus exercises option to acquire CartiHeal for $315M

Bioventus Inc. exercised its call option to acquire CartiHeal Ltd. for approximately $315 million, with an additional $135 million contingent on sales milestones, following FDA approval of CartiHeal's Agili-C implant.

- Type: Acquisition
- Announced: 2022-04-04
- Value: $315.0M
- Status: announced
- Products: Agili-C implant for cartilage regeneration
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bioventus Inc.](https://endata.com/companies/54140.md) (acquirer)
- [CartiHeal](https://endata.com/companies/57427.md) (target)

## Sources

- [bioventus.com](https://www.bioventus.com/bioventus-exercises-call-option-to-acquire-cartiheal/), 2022-04-04: "CartiHeal represents an important breakthrough for the treatment of osteoarthritis, and we are excited to bring this complementary product into our growing portfolio of medical devices."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.